Welcome to our dedicated page for MDNA news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on MDNA stock.
Medicenna Therapeutics (MDNA) provides this comprehensive news hub for stakeholders following advancements in targeted immunotherapies. Access verified updates on clinical-stage developments, research breakthroughs, and strategic partnerships driving innovation in cancer treatment.
Our curated news collection delivers essential information about MDNA's pipeline progress, including updates on IL-2/IL-4/IL-13 superkines, Empowered Cytokines research, and the T-MASK platform development. Investors and researchers will find timely reports on clinical trial milestones, regulatory developments, and collaborative research initiatives.
Key content categories include treatment efficacy data, intellectual property updates, and management commentary on therapeutic applications. All materials maintain rigorous standards for medical and financial accuracy, ensuring reliable decision-making support.
Bookmark this page for direct access to Medicenna's official communications and third-party analyses. Check regularly for updates on novel cytokine engineering approaches and their potential to transform oncology care paradigms.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) has received U.S. Patent No. 11,352,402, which covers methods for treating degenerative diseases using IL-4 and IL-13 Empowered Superkines combined with Bcl-2 family proteins. This patent, extending protection to at least 2038, enhances Medicenna's intellectual property portfolio and supports its pipeline in targeting diseases like Alzheimer’s and Parkinson’s. The company plans to leverage its robust preclinical data to pursue partnerships that can advance these assets while focusing on oncology.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) will hold a conference call on June 22, 2022, at 8:30 AM ET to discuss its fiscal year 2022 financial results and operational highlights. The call can be accessed at 1-877-407-9716 (Canada/US) or 1-201-493-6779 (international), using conference ID: 13729367. Medicenna focuses on immunotherapy, developing enhanced IL-2, IL-4, and IL-13 Superkines. Notably, their IL-2 Superkine, MDNA11, aims to improve cancer treatment by selectively targeting effector T cells and NK cells, while MDNA55 has advanced through multiple clinical trials.
Medicenna Therapeutics (NASDAQ: MDNA) presented new data from its Phase 1/2 ABILITY study of MDNA11, a long-acting IL-2 super-agonist, at the Frontiers in Cancer Immunotherapy Meeting. The results demonstrated a 2-fold increase in lymphocytes and a 3-fold increase in Granulysin-expressing immune cells without raising eosinophils, linked to toxicity. MDNA11 also selectively enhanced anti-tumor CD8+ T cells while avoiding immunosuppressive Treg cell stimulation. The study continues to enroll patients, with an efficacy update anticipated in mid-2022.
Medicenna Therapeutics (NASDAQ: MDNA) has announced promising clinical data from its Phase 1/2 ABILITY study of MDNA11, an IL-2 super-agonist, indicating significant stimulation of cancer-fighting immune cells. The third cohort (30 µg/kg dose) showed a 17-fold increase in Ki67+ expression by CD8+ T cells, and a 10-fold increase in NK cells compared to baseline. The study reports a strong safety profile with no dose-limiting toxicities and emphasizes MDNA11's potential superiority over existing therapies as dose escalation continues.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 3:00 PM EDT in Toronto. CEO Dr. Fahar Merchant and CFO Elizabeth Williams will provide a corporate overview. This conference connects investors with updates from prominent Canadian healthcare companies. Medicenna focuses on immunotherapy advancements, including its long-acting IL-2 Superkine, MDNA11, and IL-4 Empowered Superkine, MDNA55, which is undergoing clinical trials for recurrent GBM.
Medicenna Therapeutics Corp. (NASDAQ: MDNA), a clinical-stage immuno-oncology company, presented new preclinical data on its innovative BiSKIT (Bi-functional Superkines for Immuno Therapy), specifically anti-PD1-MDNA109FEAA, at the AACR Annual Meeting. The data revealed significant improvements in tumor growth inhibition and survival rates when using this novel treatment compared to standard co-administration of individual components. The BiSKIT combines anti-PD1 with an IL-2 super-agonist, enhancing anti-cancer immune cell function while preventing their exhaustion, showcasing the potential of Medicenna's Superkine platform.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced promising preclinical results for its IL-13 super-antagonist, Fc-MDNA413, presented at the AACR Annual Meeting. This novel treatment targets the Type II IL-4 receptor in tumor microenvironments, particularly effective against immunologically “cold” tumors like pancreatic and prostate cancer. Experiments demonstrated that Fc-MDNA413 successfully inhibits tumor growth, both alone and in combination with an IL-2 super-agonist. This data marks a significant step in immunotherapy for challenging cancer types.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced on March 10, 2022, that Dr. Fahar Merchant, President and CEO, will present at the 32nd Annual Oppenheimer Healthcare Conference from March 15 to March 17, 2022. The presentation is scheduled for 8:00 a.m. EST on March 15. A webcast link is provided for attendees. Medicenna focuses on immunotherapy, exploring innovative treatments such as its long-acting IL-2 Superkine, MDNA11, and MDNA55, aimed at addressing challenging cancers, including glioblastoma.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the acceptance of two abstracts for electronic poster presentations at the AACR Annual Meeting from April 8-13, 2022, in New Orleans. The abstracts focus on preclinical studies of therapeutic candidates from Medicenna’s BiSKITs™ program, showcasing innovative approaches to activate anti-cancer immune responses while minimizing exhaustion. This includes an anti-PD1-IL2 Super-Agonist and a long-acting IL-13 Super-Antagonist targeting tumor-associated macrophages. Details on the posters will be available on the AACR website and the Company’s site.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced the formation of a Clinical Advisory Board (CAB) comprising leading experts, including Dr. Kapil Dhingra as a Strategic Advisor. The CAB aims to advance Medicenna’s oncology pipeline with insights from its members, who have extensive experience in cancer therapy development. Dr. Dhingra's background includes guiding drugs to approval at Roche. The company also noted the departure of Dr. Kevin Moulder as Chief Scientific Officer to pursue other opportunities. Medicenna focuses on developing next-generation IL-2 therapies and other immunotherapeutics.
